A Phase 1/2 Single-center Study Evaluating the Safety and Efficacy of TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T Cell (ATHENA) Therapy in Adults With Refractory/Relapsed B-cell Non-Hodgkin Lymphoma
Latest Information Update: 19 Feb 2025
At a glance
- Drugs ET 901 (Primary) ; Cyclophosphamide; Fludarabine
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; First in man; Therapeutic Use
- 04 Jun 2024 Results (n=6) assessing safety of ET-901 in patients with r/r B-NHL presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 07 Sep 2023 Planned number of patients changed from 18 to 30.
- 07 Sep 2023 Status changed from not yet recruiting to recruiting.